Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 3/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28408353 | 0.93 | KDM1A (0.37) | KDM1ACHRNA3CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL23012629 | 0.82 | HRH3 (0.41) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNB1 | |
| SCHEMBL18479320 | 0.80 | KDM1A (0.40) | KDM1APARP15PARP10PARP2CHRNA3 | |
| SCHEMBL20469383 | 0.75 | EP300 (0.40) | KDM1APARP15PARP10PARP2EP300 | |
| SCHEMBL1109070 | 0.74 | CDK2 (0.40) | KDM1APARP15PARP10EP300MCHR1 | |
| SCHEMBL15687850 | 0.73 | MAP4K4 (0.42) | PARP15PARP10PARP2ACACB | |
| SCHEMBL30350762 | 0.72 | MCHR1 (0.48) | KDM1AMCHR1 | |
| SCHEMBL15776619 | 0.72 | CNR2 (0.49) | — | |
| SCHEMBL3270929 | 0.72 | KDM1A (0.37) | KDM1AEP300MCHR1 | |
| SCHEMBL19510612 | 0.72 | MCHR1 (0.48) | KDM1AMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2021-06-01 | — | — | US | disclosed |
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2021-06-01 | — | — | US | disclosed |
| US-20200230123-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2020-07-23 | — | — | US | disclosed |
| US-20200230123-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2020-07-23 | — | — | US | disclosed |
| EP-3676248-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc. (JP) | 2020-07-08 | — | — | EP | disclosed |
| CN-111132961-A | Bisaryloxy derivatives as TTX-S blockers | 拉夸里亚创药株式会社 | 2020-05-08 | — | — | CN | disclosed |
| WO-2019045035-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | SCN1B, SCN3A, SCN2B | KDM1A 2940/4885PARP15 2423/4885PARP10 2510/4885 |
| US-20200230123-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN3A, SCN2B | KDM1A 2940/4885PARP15 2423/4885PARP10 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.